In medulloblastoma, following in vitro treatment with the MKI Dasatinib resulted in reduced mesenchymal migration via downregulation of ERK1/2 in the majority of cells; however, in a subset low‐level Erk1/2 activity was preserved. This evidence concerns the gene MAPK3 and medulloblastoma.